Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Revenue for 7 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue fell 61.17% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $39.2 million, a 16.7% decrease, with the full-year FY2025 number at $39.2 million, down 16.7% from a year prior.
  • Revenue was $2.9 million for Q4 2025 at Kymera Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $47.9 million in Q4 2023 to a low of $2.8 million in Q3 2025.
  • A 5-year average of $14.2 million and a median of $11.5 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: soared 463.23% in 2021, then plummeted 84.56% in 2024.
  • Kymera Therapeutics' Revenue stood at $15.3 million in 2021, then increased by 5.66% to $16.1 million in 2022, then soared by 196.7% to $47.9 million in 2023, then tumbled by 84.56% to $7.4 million in 2024, then tumbled by 61.17% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Revenue are $2.9 million (Q4 2025), $2.8 million (Q3 2025), and $11.5 million (Q2 2025).